ANALYST CALL: Coming to America: Sandoz Files the First Biosimilar in the United States


• Sandoz's biosimilar filgrastim development program

• Zarzio's European performance

• U.S. oncologists' expected uptake of biosimilar filgrastim

• U.S. payers' price expectations and strategy to drive uptake

• Competitive landscape for biosimilars in the United States

• Potential differentiation strategies

• Next milestones for the U.S. biosimilar market

• Q&A

Login to access report